Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2024 · 10-K
Revenue$10.44M$10.44M+11.6% vs Q4 2023 Net Income-$1.90M-$1.90MN/M vs Q4 2023 EPS Diluted-$0.14-$0.14N/M vs Q4 2023 Operating Income-$1,842,039N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,902,335+91.9% Margins · derivedOperating margin-17.7%+48.4 pt vs Q4 2023
Net margin-18.2%+49.1 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 7, 2025 · 66 d after period end